Commerce Bank Has $5.09 Million Position in Zimmer Biomet Holdings Inc (NYSE:ZBH)

Commerce Bank cut its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 4.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 50,370 shares of the medical equipment provider’s stock after selling 2,216 shares during the quarter. Commerce Bank’s holdings in Zimmer Biomet were worth $5,091,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in ZBH. Dean Capital Management grew its position in shares of Zimmer Biomet by 1.3% during the 4th quarter. Dean Capital Management now owns 5,196 shares of the medical equipment provider’s stock worth $778,000 after buying an additional 68 shares during the period. 1ST Source Bank grew its position in shares of Zimmer Biomet by 0.6% in the 4th quarter. 1ST Source Bank now owns 12,890 shares of the medical equipment provider’s stock valued at $1,929,000 after purchasing an additional 72 shares during the period. Baird Financial Group Inc. lifted its stake in Zimmer Biomet by 0.3% in the 4th quarter. Baird Financial Group Inc. now owns 28,209 shares of the medical equipment provider’s stock valued at $4,222,000 after acquiring an additional 72 shares in the last quarter. Brookstone Capital Management lifted its stake in Zimmer Biomet by 1.8% in the 4th quarter. Brookstone Capital Management now owns 4,347 shares of the medical equipment provider’s stock valued at $651,000 after acquiring an additional 76 shares in the last quarter. Finally, United Bank lifted its stake in Zimmer Biomet by 0.7% in the 4th quarter. United Bank now owns 11,031 shares of the medical equipment provider’s stock valued at $1,651,000 after acquiring an additional 77 shares in the last quarter. 86.61% of the stock is owned by institutional investors and hedge funds.

In related news, CEO Bryan C. Hanson acquired 1,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $113.00 per share, for a total transaction of $113,000.00. Following the completion of the transaction, the chief executive officer now directly owns 54,568 shares of the company’s stock, valued at $6,166,184. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.44% of the stock is owned by company insiders.

ZBH has been the topic of a number of analyst reports. Zacks Investment Research upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $173.00 price objective on the stock in a research note on Saturday, February 8th. Stifel Nicolaus increased their price target on Zimmer Biomet from $111.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Credit Suisse Group dropped their price target on Zimmer Biomet from $125.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, March 6th. SunTrust Banks increased their price target on Zimmer Biomet from $125.00 to $132.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, SVB Leerink increased their price target on Zimmer Biomet from $130.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Six investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and two have given a strong buy rating to the stock. Zimmer Biomet presently has an average rating of “Buy” and a consensus target price of $146.72.

NYSE:ZBH opened at $123.40 on Friday. The stock’s 50-day simple moving average is $112.68 and its 200 day simple moving average is $133.27. The firm has a market capitalization of $25.18 billion, a PE ratio of 68.18, a price-to-earnings-growth ratio of 4.41 and a beta of 1.32. The company has a quick ratio of 1.03, a current ratio of 1.69 and a debt-to-equity ratio of 0.65. Zimmer Biomet Holdings Inc has a twelve month low of $74.37 and a twelve month high of $161.11.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Monday, May 11th. The medical equipment provider reported $1.70 EPS for the quarter, beating the consensus estimate of $1.53 by $0.17. The firm had revenue of $1.78 billion during the quarter, compared to the consensus estimate of $1.79 billion. Zimmer Biomet had a return on equity of 13.29% and a net margin of 4.84%. The business’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period last year, the company earned $1.87 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings Inc will post 4.03 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Friday, March 27th were given a $0.24 dividend. The ex-dividend date of this dividend was Thursday, March 26th. This represents a $0.96 annualized dividend and a yield of 0.78%. Zimmer Biomet’s dividend payout ratio is presently 12.20%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: What is a trade deficit?

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.